PGEN
ANALYST COVERAGE15 analysts
BUY
+161.0%upside to target
Buy
1173%
Hold
320%
Sell
17%
11 Buy (73%)3 Hold (20%)1 Sell (7%)
Full report →
PRICE
Prev Close
4.42
Open
4.42
Day Range4.19 – 4.46
4.19
4.46
52W Range1.28 – 5.47
1.28
5.47
70% of range
VOLUME & SIZE
Avg Volume
4.5M
FUNDAMENTALS
P/E Ratio
-3.5x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.56
High vol
TECHNICAL
RSI (14)
63
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 94 days
Aug 20
Key MetricsTTM
Market Cap$1.26B
Revenue TTM$31.59M
Net Income TTM-$204.42M
Free Cash Flow-$117.57M
Gross Margin75.6%
Operating Margin-297.2%
Net Margin-647.0%
Return on Equity-1768.5%
Return on Assets-147.5%
Debt / Equity4.86
Current Ratio4.82
EPS TTM$-0.65

PGEN News

About

precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Helen Sabzevari
Bryan T. ButmanSenior Vice President & Head of CMC
Douglas E. BroughSenior Vice President & Head of Research
Harry Thomasian Jr.Chief Financial Officer
Phil TennantChief Commercial Officer
Randal J. KirkExecutive Chairman
Rob RussellVice President & Head of Human Resources
Rutul R. ShahChief Operating Officer
Steven HarasymVice President & Head of Investor Relations
Helen SabzevariPresident, Chief Executive Officer & Director
Donald LehrChief Legal Officer & Corporate Secretary